Zobrazeno 1 - 10
of 29
pro vyhledávání: '"E Tevar"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Merino Alonso, MJ Castillo Méndez, A Ferrer Machín, K Álvarez Tosco, MA Ocaña Gomez, ML Padilla Salazar, M Hayek Peraza, J Ode Febles, E Tevar, L Abella Vázquez
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance The implementation of an antimicrobial stewardship programme (AMSP) is very important but it has to be accompanied by personnel resources. It is therefore necessary to effectively use the time spent in the AMSP reviewing onl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::308e5628747ae3a7267e14436990f8e6
https://doi.org/10.1136/ejhpharm-2020-eahpconf.21
https://doi.org/10.1136/ejhpharm-2020-eahpconf.21
Autor:
M Vera Cabrera, K Álvarez Tosco, MA Ocaña Gomez, JA Martin Conde, A. de León Gil, I Plasencia García, FJ Merino Alonso, C Perez Martin, R Mesa Expósito, E Tevar Alonso, A Ferrer Machín
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The problem of severe asthma refractory to treatment has been addressed in clinical practice guidelines but there is still a notable percentage of patients poorly controlled, under treated and with inadequate follow-up. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66bcb84821972966e33ef9fac8bbb1c5
https://doi.org/10.1136/ejhpharm-2020-eahpconf.246
https://doi.org/10.1136/ejhpharm-2020-eahpconf.246
5PSQ-041 Efficacy and safety of cidofovir in the treatment of laryngeal papillomatosis: case reports
Autor:
M Viña, I Plasencia, J Merino, R Mesa, L Diaz, E Tevar, A Ocaña, M Navarro, I Gonzalez, A Puebla
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Laryngeal papillomatosis is a larynx neoplasm due to the human papillomavirus virus (HPV) infection. It can appear during the first year of life, or during adulthood, which increases the probability of becoming malignant. It is characteris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa7cdb4d0fc7b5ed0fd2d49d04e5f5f3
https://doi.org/10.1136/ejhpharm-2019-eahpconf.474
https://doi.org/10.1136/ejhpharm-2019-eahpconf.474
Autor:
F. Pérez Hernández, R Mesa Expósito, I González García, Mdp Díaz Ruiz, E Tevar Afonso, M Suarez Gonzalez, FJ Merino Alonso, AM Gonzalez Rodriguez, CL Diaz Diaz, MA Navarro Dávila
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Obeticholic acid (OCA) is a synthetically modified bile acid that is used to treat a rare disease, the primary biliary cholangitis (PBC). OCA has been recently used in combination with ursodeoxycholic acid (UDCA) in adults who have not res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b868e2c9e842d7ad22ad7e9ca2f1ecb
https://doi.org/10.1136/ejhpharm-2019-eahpconf.434
https://doi.org/10.1136/ejhpharm-2019-eahpconf.434
Autor:
P Olvera, M Suarez Gonzalez, E Tevar Alonso, FJ Merino Alonso, MA Ocaña Gomez, M Vera Cabrera, I Plasencia García, A Ferrer Machín, E Gómez Melini, JA Morales Barrios, R Mesa Expósito
Publikováno v:
Eur J Hosp Pharm
Background Diabetes is a chronic pathology of high prevalence and a large number of associated comorbidities that have an impact on patients’ quality of life. In the hospital environment, poor insulin adherence may lead to episodes of hyperglycaemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c53498467d3bc9c902bbdaf6d1bc14
https://europepmc.org/articles/PMC7535421/
https://europepmc.org/articles/PMC7535421/
Autor:
J Merino, E Gomez, T Betancor, Miguel Angel Cajigal Vera, I Plasencia, G Calzado, A Ferrer, E Tevar, E Ramos, M Navarro, M Suárez
Publikováno v:
Eur J Hosp Pharm
Background We ask if dalvabancina and tedizolid are good alternatives for strains with reduced sensitivity to vancomycin, daptomycin or linezolid. Purpose To determine the most cost-effective treatment option for GRAM +microorganisms with reduced sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd2597761123526e165efb978178326
https://doi.org/10.1136/ejhpharm-2018-eahpconf.148
https://doi.org/10.1136/ejhpharm-2018-eahpconf.148
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E Tevar, P Díaz, JC Febles, E Marqués, MA Ocaña-Gomez, A De León-Gil, T Betancor-Garcia, J Merino, S Ramos-Linares, I Plasencia-Garcia
Publikováno v:
European Journal of Hospital Pharmacy. 23:A215.2-A216
Background In 2013, our protocol of restricted use antibiotics (RUA) was updated and computerised. The following drugs were subject to their respective indications. Ertapenem: community intra-abdominal infection with risk factors, moderate or severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0f97839ce6e781a94c101959c0c4950
https://doi.org/10.1136/ejhpharm-2016-000875.488
https://doi.org/10.1136/ejhpharm-2016-000875.488